Try our Advanced Search for more refined results

Astellas Beats Generics' Bid To Nix Cancer Drug Patent

By Hanna Vioque ( July 23, 2025, 8:27 PM BST) -- Generic-drug makers on Wednesday failed to convince a London appellate judge to nix remaining protections for Astellas Pharma's blockbuster prostate cancer treatment Xtandi because the evidence provided was "tainted with hindsight."...

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Law Firms

Companies

Government Agencies